Peter MacCallum Cancer Centre, Radiation Oncology Department, Moorabbin Campus, East Bentleigh Victoria 3165, Australia.
Universita degli Studi di Parma, Department of Clinical and Experimental Medicine, Experimental Oncology Unit, Via Gramsci, 14, Parma, Italy.
Crit Rev Oncol Hematol. 2017 Apr;112:208-214. doi: 10.1016/j.critrevonc.2017.02.022. Epub 2017 Feb 24.
Notwithstanding the continuous progress made in cancer treatment in the last 20 years, and the availability of new targeted therapies, metastatic Breast Cancer (BC) is still incurable. Targeting the cell cycle machinery has emerged as an attractive strategy to tackle cancer progression, showing very promising results in the preclinical and clinical settings. The first selective inhibitors of CDK4/6 received breakthrough status and FDA approval in combination with letrozole (February 2015) and fulvestrant (February 2016) as first-line therapy in ER-positive advanced and metastatic BC. Considering the success of this family of compounds in hormone-positive BC, new possible applications are being investigated in other molecular subtypes. This review summarizes the latest findings on the use of CDK4/6 inhibitors in HER2 positive BC.
尽管在过去 20 年中癌症治疗取得了持续进展，并且出现了新的靶向治疗方法，但转移性乳腺癌（BC）仍然无法治愈。针对细胞周期机制已成为一种有吸引力的策略，可以解决癌症进展问题，在临床前和临床环境中显示出非常有前途的结果。CDK4/6 的首个选择性抑制剂与来曲唑（2015 年 2 月）和氟维司群（2016 年 2 月）联合作为 ER 阳性晚期和转移性 BC 的一线治疗获得了突破性地位和 FDA 批准。鉴于该类化合物在激素阳性 BC 中的成功，正在其他分子亚型中研究新的可能应用。本文综述了 CDK4/6 抑制剂在 HER2 阳性 BC 中的最新应用研究进展。
